Description: Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, focuses on the development of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing an unmodified phytocannabinoid combination for orphan indications in neuropathic pain. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Home Page: www.oxcantech.com
Prama House
Oxford,
OX2 7HT
United Kingdom
Phone:
44 20 3034 2820
Officers
| Name | Title |
|---|---|
| Ms. Clarissa Ann Sowemimo-Coker | CEO & Executive Director |
| Mr. Indraneil Mahapatra | Co-Founder & Non-Executive Director |
| Mr. Paul William Smalley | CFO, Finance Director & Executive Director |
| Dr. Valentino Parravicini | Chief Scientific Officer |
| Mr. Robin Bennett | General Counsel & Company Secretary |
| Dr. Timothy Henry Corn FFPM, M.Sc. | Executive Director & Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2205 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 0 |